EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Acute Changes in Kidney Function and Outcomes Following an Acute Myocardial Infarction: Insights from PARADISE-MI

Finnian R Mc Causland iD, Martina M McGrath, Brian L Claggett, Ebrahim Barkoudah, Cara East, Alberto Fernandez, Karola S Jering, Eldrin F Lewis, John J V McMurray, Freny Vaghaiwalla Mody, Scott D Solomon, Mariya Tokmakova und 3 weitere

European Journal of Heart Failure · 2024

DOI: 10.1002/ejhf.3386 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Heart Failure, 2024. Verfasst von Finnian R Mc Causland und 14 weiteren Autor:innen. Beteiligte Einrichtung: Renal Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. Hauptthemen laut MEDLINE: Aminobutyrates, Angiotensin Receptor Antagonists, Drug Combinations, Glomerular Filtration Rate. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 16 Literaturangaben. Gefördert von: Novartis Pharmaceuticals Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Pharmacologic blockade of neurohormonal pathways in patients with acute myocardial infarction (MI) can result in acute changes in biomarkers of kidney function. We evaluated the effect of sacubitril/valsartan versus ramipril on initial changes in serum creatinine and the association of these changes with longer-term outcomes among participants in PARADISE-MI. Methods and results In this randomized, double-blind, active-controlled, event-driven trial, 5661 patients with an acute MI were assigned to receive sacubitril/valsartan or ramipril, with no run-in. The frequency of an initial pre-specified increase in serum creatinine (≥26.5 or ≥44 μmol/L) from baseline to week 1 was compared between arms. Multivariable Cox regression models were fit to examine the association of acute changes in serum creatinine with the primary cardiovascular composite outcome (cardiovascular death, first heart failure hospitalization, or outpatient heart failure), all-cause mortality, and longer-term changes in estimated glomerular filtration rate (eGFR). An initial increase in serum creatinine ≥26.5 μmol/L occurred in 155 of 2604 (6.0%) patients assigned to sacubitril/valsartan and 120 of 2603 (4.6%) patients assigned to ramipril (odds ratio [OR] 1.32; 95% confidence interval [CI] 1.03–1.68). The corresponding numbers for an increase ≥44 μmol/L were 57 (2.2%) and 42 (1.6%), respectively (OR 1.37; 95% CI 0.92–2.05). A higher odds of increased serum creatinine ≥26.5 and ≥44 μmol/L for sacubitril/valsartan versus ramipril appeared to be restricted to patients who had a greater decline in systolic blood pressure over the same period (p-interaction = 0.05 and 0.001, respectively). In multivariable analyses, neither an acute increase in serum creatinine ≥26.5 or ≥44 μmol/L was associated with a higher risk of cardiovascular outcomes, all-cause mortality, or differences in longer-term eGFR slope. Findings were similar across the randomized treatment arms (p-interaction >0.6 for all).

Conclusions

Following acute MI, patients assigned to sacubitril/valsartan had a higher frequency of initial increases in serum creatinine at 1 week, compared with ramipril. In adjusted models, initial increases in serum creatinine with either treatment were not associated with adverse cardiovascular outcomes or changes in longer-term kidney function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AminobutyratesAngiotensin Receptor AntagonistsDrug CombinationsGlomerular Filtration RateMyocardial InfarctionRamiprilValsartanAgedFemaleHumansMaleMiddle AgedAngiotensin-Converting Enzyme InhibitorsBiomarkersBiphenyl CompoundsCreatinineDouble-Blind MethodHeart FailureKidneyTetrazolesTreatment Outcome

Stichwörter der Autor:innen

Angiotensin receptor–neprilysin inhibitorChronic kidney diseaseMyocardial infarctionSacubitril/valsartanWorsening renal function

Substanzen

AminobutyratesAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsBiomarkersBiphenyl CompoundsCreatinineDrug CombinationsRamiprilsacubitril and valsartan sodium hydrate drug combinationTetrazoles

Autor:innen und Institutionen

  • Renal Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
  • Harvard Medical School, Boston, MA, USA.
  • Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
  • Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
  • Baylor Soltero CV Research Center, Baylor Scott and White Heart and Vascular Hospital, Dallas, TX, USA.
  • Cardiology Service, Sanatorio Modelo Quilmes, Quilmes, Argentina.

ORCID-Profile: Finnian R Mc Causland

Förderung

  • Novartis Pharmaceuticals Corporation

Zitieren

APA

Mc Causland, F. R., McGrath, M. M., Claggett, B. L., Barkoudah, E., East, C., Fernandez, A., Jering, K. S., Lewis, E. F., McMurray, J. J. V., Mody, F. V., Solomon, S. D., Tokmakova, M., van der Meer, P., Zhou, Y., & Pfeffer, M. A. (2024). Acute Changes in Kidney Function and Outcomes Following an Acute Myocardial Infarction: Insights from PARADISE-MI. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.3386

Vancouver

Mc Causland FR, McGrath MM, Claggett BL, Barkoudah E, East C, Fernandez A, et al. Acute Changes in Kidney Function and Outcomes Following an Acute Myocardial Infarction: Insights from PARADISE-MI. European Journal of Heart Failure. 2024. doi:10.1002/ejhf.3386

BibTeX
@article{McCausland2024,
  author = {Mc Causland, Finnian R and McGrath, Martina M and Claggett, Brian L and Barkoudah, Ebrahim and East, Cara and Fernandez, Alberto and Jering, Karola S and Lewis, Eldrin F and McMurray, John J V and Mody, Freny Vaghaiwalla and Solomon, Scott D and Tokmakova, Mariya and van der Meer, Peter and Zhou, Yinong and Pfeffer, Marc A},
  title = {Acute Changes in Kidney Function and Outcomes Following an Acute Myocardial Infarction: Insights from PARADISE-MI},
  journal = {European Journal of Heart Failure},
  year = {2024},
  doi = {10.1002/ejhf.3386}
}
Kostenlos starten →